Spectrophotometric determination of pramipexole di-hydrochloride in bulk and tablet dosage form

Abstract

Pramipexole dihydrochloride is chemically (s)-2-amino 4, 5, 6, 7 tetra hydro-6 (propylamino) benzothiazole dihydrochloride is used as an anti-Parkinsons drug. The drug is commercially accessible as tablets for oral administration. In the present work an attempt has been made to estimate the drug by three methods. Method A is absorption maxima method in which λ_max was found to be 262nm. Method B is first order derivative spectroscopy where drug showed λmaxima=278nm and λminima=246nm.In this method amplitude difference (dA/dλ) was calculated and was plotted against concentration and regression equation was calculated. Method C is area under the curve (AUC) in which area in the wavelength range of 258nm - 266nm was selected for analysis of Pramipexole. Linearity was observed in the concentration range 10-50μg/ml (r² =0.999) for all the three methods. The % assay for the marketed formulation for absorption maxima, first order derivative and area under the curve method was found to be 102.11%, 99.41% and 103.1% respectively. The methods were validated with respect to linearity, precision and accuracy studies. Recovery studies for absorption maxima, first order derivative and area under the curve was found to be 101.4%, 100.1% and 100.52% respectively. The methods were found to be simple, rapid, economical, precise and accurate and can be employed for routine quality control analysis of Pramipexole in bulk as well as from its dosage form.